MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/1/2025
-
Ticker Report
3/19/2025
-
ETF Channel
3/19/2025
-
GuruFocus
3/19/2025
-
GuruFocus
3/18/2025
-
Seeking Alpha: Transcripts
3/18/2025
-
SeekingAlpha
3/18/2025
-
GuruFocus
3/18/2025
-
The Fly
3/18/2025
-
Globe Newswire
3/5/2025
-
Simply Wall St
3/4/2025
-
GuruFocus
3/4/2025
-
Globe Newswire
3/2/2025
-
Ticker Report
2/25/2025
-
Ticker Report
2/24/2025
-
GuruFocus
2/24/2025
-
TipRanks Financial Blog
2/24/2025
-
The Fly
2/24/2025
-
Globe Newswire
2/20/2025
-
GuruFocus
2/20/2025
-
TipRanks Financial Blog
2/20/2025
-
The Fly
2/20/2025
-
Globe Newswire
2/14/2025
-
ETF Channel
2/12/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 18, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
212 994 8250
Address
149 Fifth Avenue
New York, NY 10010
New York, NY 10010
Country
Year Founded
Business Description
Sector
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT)...
more
